A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma

Pediatric Pulmonology

Volumn 46, Issue 8, 2011, Pages 761-769

  Hinkle, J ^a   Hinson, J ^b   Kerwin, E ^c   Goodwin, E ^a   Sciarappa, K ^a   Curry, L ^a   Hanrahan, J P ^a,d  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b Unicorn Pharma   (United States)

^c Clinical Research Institute of Southern Oregon   (United States)

^d PULMATRIX INC   (United States)

Author keywords

arformoterol; asthma; levalbuterol; long acting 2 agonist; pediatrics; safety

Indexed keywords

ARFORMOTEROL; GLUCOSE; LEVALBUTEROL; POTASSIUM;

ARTICLE; ASTHMA; BLOOD PRESSURE; CHILD; CHILDHOOD DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART RATE; HOSPITALIZED CHILD; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OFF LABEL DRUG USE; PEAK EXPIRATORY FLOW; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCHOOL CHILD;

ALBUTEROL; ASTHMA; BLOOD GLUCOSE; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; OFF-LABEL USE; POTASSIUM;

EID: 79960354736     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21446     Document Type: Article

References (12)

1. Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120: S94-S138.
2. GINA-The global initiative for asthma. 2008. (Accessed on May 13, 2009).
3. Brovana™ (arformoterol tartrate) Inhalation Solution [package insert]. 2007.
4. CDER. Summary minutes of the Joint Pulmonary-Allergy Drugs Advisory Committee (PADAC), Drug Safety and Risk Management Advisory Committee (DSaRM), and Pediatric Advisory Committee (PAC). FDA [serial online] 2010; (Accessed on March 10, 2010).
5. Kramer JM,. Balancing the benefits and risks of inhaled long-acting beta-agonists-The influence of values. N Engl J Med 2009; 360: 1592-1595.
6. Chowdhury BA, Dal Pan G,. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. NEJM 2010; 362: 1169-1171.
7. NHLBI, National Asthma Education and Prevention Program Coordinating Committee. Expert panel report 3: Guidelines for the diagnosis and management of asthma. 97-4051, 1-153. 2007.
8. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. 2008.
9. Avila-Castanon L, Casas-Becerra B, Del Rio-Navarro BE, Velazquez-Armenta Y, Sienra-Monge JJL,. Formoterol vs. albuterol administered via turbuhaler system in the emergency treatment of acute asthma in children. Allergol et Immunopathol 2004; 32: 18-20. (Pubitemid 38374688)
10. Bussamra MH, Stelmach R, Rodrigues JC, Cukier A,. A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. Ann Allergy Asthma Immunol 2009; 103: 248-253.
11. Rodriguez E, Vera V, Perez-Puigbo A, Capriles-Hulett A, Ferro S, Manrique J, Abate J,. et al. Equivalence of a single saline nebulised dose of formoterol powder vs. three doses of nebulised albuterol every twenty minutes in acute asthma in children: A suitable cost effective approach for developing nations. Allergol et Immunopathol 2008; 36: 196-200.
12. Xopenex product information. [serial online] 2005.